atrial fibrillation, heart failure
DISEASE INTERVENTION COMPARISON RESULTS
J Card Fail. 2007 Jun;13(5):340-5. Controlled Trial (non-randomized)
IN antiarrthythmic drugs, amiodarone, adverse effects, mortality, atrial fibrillation, heart failure The Use of
amiodarone
As Treatment, Chronic
Is worse Than
no amiodarone
To mortality: risk of death due to circulatory failure with amiodarone: HR 1.5
Am J Cardiol. 2003 Mar 20;91(6A):2D-8D Review (Narrative)
IN atrial fibrillation, heart failure The Use of
incidence, prevalence, patophysiology
As -
Is useful Than
-
To Different factors create an environment in which HF predisposes to AF and AF exacerbates HF. Although therapeutic options for AF are varied, their effect on prognosis remains unknown.
N Engl J Med. 2004 Dec 2;351(23):2373-83 Clinical Trial (non-controlled, non-randomized)
IN atrial fibrillation, heart failure, non-pharmacological treatment The Use of
catheter ablation, radiofrequency
As -
Is good Than
no relevant comparison group in this trial
To restore and maintain sinus rhythm: after 12 months 70% of patients maintained SR. Improve ejection fraction in those patients with heart failure (average of plus 20% at 12 months)
N Engl J Med. 2018 02 01;378(5):417-427 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, heart failure, systolic (reduced ejection fraction), non-pharmacological treatment The Use of
catheter ablation, radiofrequency
As Treatment, Acute
Is better Than
medical therapy (rate or rhythm control)
To reduce at 3 years a composite of all-cause death from or hospitalization for heart failure: 29% ablation VS 45% medical Tt. Significantly fewer patients in the ablation group died from any cause: 13% VS 25.0%
Circulation. 1998 Dec 8;98(23):2574-9 Randomized Controlled Trial, Multicenter Trial
IN StudyID: CHF-STAT 1998, atrial fibrillation, heart failure The Use of
amiodarone
As Treatment, Chronic
Is better Than
placebo
To mortality, AF recurrence - at 12 months
Circulation. 2003 Jun 17;107(23):2926-31 Randomized Controlled Trial
IN StudyID: Vermes 2003, atrial fibrillation, heart failure The Use of
angiotensing converting enzyme inhibitors, enalapril
As Treatment, Chronic
Is better Than
placebo
To reducing the risk of development of atrial fibrillation in patients with left ventricular dysfunction (at 3 years: 5,4% ACEi vs 24% placebo)